193 related articles for article (PubMed ID: 30548174)
1. Molecular characterization of an MLL1 fusion and its role in chromosomal instability.
Parameswaran S; Vizeacoumar FS; Kalyanasundaram Bhanumathy K; Qin F; Islam MF; Toosi BM; Cunningham CE; Mousseau DD; Uppalapati MC; Stirling PC; Wu Y; Bonham K; Freywald A; Li H; Vizeacoumar FJ
Mol Oncol; 2019 Feb; 13(2):422-440. PubMed ID: 30548174
[TBL] [Abstract][Full Text] [Related]
2. A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
Song X; Yang L; Wang M; Gu Y; Ye B; Fan Z; Xu RM; Yang N
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):19917-19923. PubMed ID: 31527241
[TBL] [Abstract][Full Text] [Related]
3. The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments.
Liu H; Lee S; Zhang Q; Chen Z; Zhang G
Mol Carcinog; 2020 Jul; 59(7):839-851. PubMed ID: 32329934
[TBL] [Abstract][Full Text] [Related]
4. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.
Milne TA; Kim J; Wang GG; Stadler SC; Basrur V; Whitcomb SJ; Wang Z; Ruthenburg AJ; Elenitoba-Johnson KS; Roeder RG; Allis CD
Mol Cell; 2010 Jun; 38(6):853-63. PubMed ID: 20541448
[TBL] [Abstract][Full Text] [Related]
5. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of mixed-lineage leukemia.
Bach C; Slany RK
Future Oncol; 2009 Oct; 5(8):1271-81. PubMed ID: 19852741
[TBL] [Abstract][Full Text] [Related]
7. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth.
Li X; Yao Y; Wu F; Song Y
J Hematol Oncol; 2022 Apr; 15(1):41. PubMed ID: 35395864
[TBL] [Abstract][Full Text] [Related]
8. The many facets of MLL1 regulation.
Zhang P; Bergamin E; Couture JF
Biopolymers; 2013 Feb; 99(2):136-45. PubMed ID: 23175388
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
10. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
Wang H; Bei L; Shah CA; Huang W; Platanias LC; Eklund EA
Oncogene; 2018 May; 37(19):2532-2544. PubMed ID: 29459712
[TBL] [Abstract][Full Text] [Related]
11. MLL1 is essential for the senescence-associated secretory phenotype.
Capell BC; Drake AM; Zhu J; Shah PP; Dou Z; Dorsey J; Simola DF; Donahue G; Sammons M; Rai TS; Natale C; Ridky TW; Adams PD; Berger SL
Genes Dev; 2016 Feb; 30(3):321-36. PubMed ID: 26833731
[TBL] [Abstract][Full Text] [Related]
12. Mixed lineage leukemia: roles in human malignancies and potential therapy.
Marschalek R
FEBS J; 2010 Apr; 277(8):1822-31. PubMed ID: 20236311
[TBL] [Abstract][Full Text] [Related]
13. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
14. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.
Zhao Z; Wang L; Volk AG; Birch NW; Stoltz KL; Bartom ET; Marshall SA; Rendleman EJ; Nestler CM; Shilati J; Schiltz GE; Crispino JD; Shilatifard A
Genes Dev; 2019 Jan; 33(1-2):61-74. PubMed ID: 30573454
[TBL] [Abstract][Full Text] [Related]
15. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
Stubbs MC; Krivtsov AV
Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
[TBL] [Abstract][Full Text] [Related]
16. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.
Bueno C; Montes R; Catalina P; RodrÃguez R; Menendez P
Leukemia; 2011 Mar; 25(3):400-10. PubMed ID: 21135858
[TBL] [Abstract][Full Text] [Related]
17. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential.
Emerenciano M; Kowarz E; Karl K; de Almeida Lopes B; Scholz B; Bracharz S; Meyer C; Pombo-de-Oliveira MS; Marschalek R
Cancer Lett; 2013 May; 332(1):30-4. PubMed ID: 23340173
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
[TBL] [Abstract][Full Text] [Related]
20. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
